MIRA logo

MIRA PHARMACEUTICALS INC

MIRANASDAQ
🏆 #4577 by market capUS Equity
$791.92▲ $62.88 (+7.94%)
Simulated price
🔔
Track MIRA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$38M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
52
Weak
No chart data available for MIRA.

Trading Snapshot

Day Range
$782.69 – $799.31
52-Week Range
$0.60 – $2.45
Volume
$2.14B
Avg Volume
$1.45B
Shares Outstanding
42.0M
Next Earnings
Dec 11, 2026

Fundamentals Snapshot

Annual Revenue
$7M
Last Q Revenue
$2M
P/E Ratio
-0.7
P/S Ratio
0.0x
EPS (TTM)
$-0.23
Dividend Yield
0.00%
Dilution (1yr)
+53.4%

Why Investors Own MIRA

  • ✓High-growth profile — revenue up +0.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 47% gross margin and 27% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MIRA logo

MIRA PHARMACEUTICALS INC

MIRA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$10M▲ +30.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▼ −16.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
23.7M▲ +53.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6M▲ +$4M YoY
StockOtter · stockotter.space

About MIRA PHARMACEUTICALS INC

MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100

Analyst Price Target

ⓘ
Average Target
$892.21
▲ +12.7% Upside
High Target$1,113.16
Low Target$749.88
Based on 19 analysts

Latest News & Updates

🚀
Reuters·2h ago

MIRA PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift MIRA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

MIRA PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.